Top Markets
Coin of the day
Agile Therapeutics, Inc. Agile Therapeutics, Inc.

Agile Therapeutics, Inc.

AGRX
Peringkat dalam Saham #38231
Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated... Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated to the research, development, and market introduction of prescription contraception in the United States. Its flagship product is Twirla (also known by its development code, AG200-15), a combined hormonal contraceptive delivered through a patch applied once weekly. The company is also progressing with several pipeline innovations, including variations of Twirla and other new products: AG200-15 Extended Regimen (ER): A regimen designed to limit a woman to four withdrawal bleeding occurrences annually. AG200-15 smaller patch (SmP): This iteration aims for shorter, lighter withdrawal bleeds and potentially enhanced contraceptive efficacy. AG200-15 ER SmP: A combined regimen that allows for an extended contraceptive cycle while simultaneously providing fewer, lighter annual bleeding episodes. P-Patch: A contraceptive patch containing only progestin, specifically intended for women who cannot or choose not to use estrogen. Agile Therapeutics, Inc. was founded in 1997 and is based in Princeton, New Jersey.
Harga Saham
$1.51
Terakhir disinkronkan: 2024-08-26
Kapitalisasi Pasar
$1.12M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Agile Therapeutics, Inc. (AGRX)

Kategori

Laba untuk Agile Therapeutics, Inc. (AGRX)
Laba pada Jun 2024 TTM: $-15.86M
Menurut laporan keuangan terbaru dari Agile Therapeutics, Inc., laba saat ini perusahaan adalah $-15.86M. Pada tahun 2022, perusahaan memperoleh laba sebesar $-30.09M, peningkatan dibandingkan laba tahun 2021 sebesar $-74.89M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Agile Therapeutics, Inc. dari 2012 hingga 2026
Laba pada akhir setiap tahun
Tahun Laba Mengubah
2026 (TTM) $-15.86M 9.62%
2023 $-14.47M -51.92%
2022 $-30.09M -59.83%
2021 $-74.89M 44.44%
2020 $-51.85M 178.69%
2019 $-18.61M -8.15%
2018 $-20.26M -28.43%
2017 $-28.30M -11.04%
2016 $-31.82M -12.37%
2015 $-36.31M 84.02%
2014 $-19.73M 37.77%
2013 $-14.32M -38.43%
2012 $-23.26M 0.00%
Laba untuk perusahaan serupa atau pesaing